Investigators aimed to identify predictors of health care utilization in patients with irritable bowel syndrome, functional constipation, and functional diarrhea.
Firvanq is indicated for the treatment of Clostridium difficile-associated diarrhea and enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains).
Investigators assessed the safety and efficacy of treatment with a selective oral transglutaminase 2 inhibitor in patients with well-controlled celiac disease.
In a post-hoc analysis, researchers assessed the effects of lenvatinib compared with sorafenib on health-related quality of life in patients with hepatocellular carcinoma.
Researchers analyzed data from patients with chronic non-cancer pain and opioid-induced constipation to determine PAC-SYM and PAC-QOL minimal clinically important difference values.
The exact pathophysiology of microscopic colitis is not completely understood, though PPIs and NSAIDs are 2 medications commonly implicated for triggering the inflammatory process.
Constipation has long been thought of as a benign condition and one better suited for self-management, but if left untreated, it could lead to a host of other medical conditions, including cardiovascular disease, shows one study in this feature.
Researchers investigated the safety and efficacy of the novel endopeptidase TAK-062 for gluten degradation in patients with celiac disease and healthy controls.
Investigators analyzed the effects of TAK-101 from the induction of gliadin-specific T-cell tolerance in patients with biopsy-confirmed celiac disease.
Irritable bowel syndrome is rarely serious, but is still an inconvenience and a painful disorder for patients who have it. For patients who have IBS or are concerned they may have it, how can you explain the basics of how it is detected and managed?
